Clinical Trials

500 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06136559 2026-04-13

BELLWAVE-011

1,200 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06428019 2026-04-09

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

170 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04529772 2026-03-31

ESCALADE

611 enrolled

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02477696 2026-03-27

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

533 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04075292 2026-03-05

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

155 enrolled 16 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

635 enrolled 3 FDA

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT05057494 2026-02-18

MAJIC

607 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07377578 2026-02-06

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

394 enrolled

Lymphoma, Mantle-Cell

NCT04008706 2025-12-01

ASSURE

Phase 3 Completed

552 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02475681 2025-08-27

ElevateTN

535 enrolled 19 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05197192 2025-08-17

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

202 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04662255 2025-05-28

BRUIN-MCL-321

500 enrolled

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03836261 2024-12-27

AMPLIFY

984 enrolled 3 FDA

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05820841 2023-08-31

ARCHED

330 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02735876 2016-05-13

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Phase 3 Withdrawn